BEACHBODY CO INC/THE (BODI) Forecast, Price Target & Analyst Ratings

NASDAQ:BODIUS0734633094

Current stock price

10.4 USD
+0.38 (+3.79%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BEACHBODY CO INC/THE (BODI).

Forecast Snapshot

Consensus Price Target

Price Target
$14.03
+ 34.86% Upside

Next Earnings Forecast

Earnings Estimate
Release Date
May 12, 2026
Period
Q1 / 2026
EPS Estimate
-$0.16
Revenue Estimate
53.214M

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$14.03
Upside
+ 34.86%
From current price of $10.40 to mean target of $14.03, Based on 10 analyst forecasts
Low
$10.10
Median
$15.30
High
$15.75

Price Target Revisions

1 Month
35.25%
3 Months
35.25%

Price Target Summary

10 Wall Street analysts provided a forecast for the next 12 months for BODI. The average price target is 14.03 USD. This implies a price increase of 34.86% is expected in the next year compared to the current price of 10.4.
The average price target has been revised upward by 35.25% in the past 3 months.

Analyst Ratings & History

Current Analyst Ratings

BODI Current Analyst RatingBODI Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

BODI Historical Analyst RatingsBODI Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
BODI was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about BODI.
In the previous month the buy percentage consensus was at a similar level.
BODI was analyzed by 10 analysts. More opinions would make the average more meaningful.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-11Canaccord GenuityMaintains Buy -> Buy
2026-03-10Canaccord GenuityMaintains Buy -> Buy
2025-11-11Canaccord GenuityMaintains Buy -> Buy
2025-04-01Roth MKMDowngrade Buy -> Neutral
2025-03-28Canaccord GenuityMaintains Buy -> Buy
2024-11-14Roth MKMReiterate Buy -> Buy
2024-07-15ThinkEquityInitiate Buy
2024-05-17Canaccord GenuityInitiate Buy
2024-05-07Roth MKMMaintains Buy -> Buy
2024-05-07BairdMaintains Neutral -> Neutral

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 12, 2026
Period
Q1 / 2026
EPS Estimate
-$0.16
Revenue Estimate
53.214M
Revenue Q2Q
-26.46%
EPS Q2Q
81.38%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
-8.16%
Revenue (3 Months)
-8.16%
EPS (1 Month)
31.85%
EPS (3 Months)
31.85%

Next Earnings Summary

BODI is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.16 USD and the consensus revenue estimate is 53.21M USD.
The next earnings revenue estimate has been revised downward by 8.16% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.

Full Analyst Estimates 2026 - 2027

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027
Revenue
YoY % growth
BODI revenue by date.BODI revenue by date.
527.109M
-23.85%
418.796M
-20.55%
251.727M
-39.89%
225.5M
-10.42%
271.69M
20.48%
EBITDA
YoY % growth
BODI ebitda by date.BODI ebitda by date.
-28.071M
62.10%
8.745M
131.15%
25.562M
192.30%
23.059M
-9.79%
30.625M
32.81%
EBIT
YoY % growth
BODI ebit by date.BODI ebit by date.
-91.399M
47.23%
-38.361M
58.03%
8.008M
120.88%
389.028K
-95.14%
14.317M
3,580.20%
Operating Margin
BODI operating margin by date.BODI operating margin by date.
-17.34%-9.16%3.18%0.17%5.27%
EPS
YoY % growth
BODI eps by date.BODI eps by date.
-17.97
43.84%
-9.55
46.86%
-0.47
95.08%
-0.44
6.14%
1.28
389.02%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth
-0.16
81.38%
-0.25
70.40%
0.05
-90.00%
0.35
-50.68%
0.48
406.53%
0.69
375.67%
0.77
1,400.00%
0.72
106.80%
Revenue
Q2Q % growth
53.214M
-26.46%
54.046M
-15.48%
59.509M
-0.63%
60.855M
9.58%
73.249M
37.65%
79.109M
46.37%
82.273M
38.25%
80.628M
32.49%
EBITDA
Q2Q % growth
4.955M
155.02%
4.048M
-52.13%
6.934M
-62.94%
9.057M
-64.81%
10.497M
111.85%
12.231M
202.15%
11.968M
72.60%
11.677M
28.93%
EBIT
Q2Q % growth
634.777K
117.28%
-514.763K
65.03%
1.548M
-68.88%
3.673M
-55.10%
4.935M
677.44%
6.643M
1,390.50%
7.182M
363.95%
6.898M
87.80%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BODI Yearly Revenue VS EstimatesBODI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
BODI Yearly EPS VS EstimatesBODI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

BEACHBODY CO INC/THE / BODI Forecast FAQ

What is the price target for BODI stock?

10 analysts have analysed BODI and the average price target is 14.03 USD. This implies a price increase of 34.86% is expected in the next year compared to the current price of 10.4.

When does BEACHBODY CO INC/THE (BODI) report earnings?

BEACHBODY CO INC/THE (BODI) will report earnings on 2026-05-12.

Can you provide the consensus estimates for BEACHBODY CO INC/THE next earnings?

The consensus EPS estimate for the next earnings of BEACHBODY CO INC/THE (BODI) is -0.16 USD and the consensus revenue estimate is 53.21M USD.

What is the consensus rating for BEACHBODY CO INC/THE (BODI) stock?

The consensus rating for BEACHBODY CO INC/THE (BODI) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.